Workflow
复星医药: 上海复星医药(集团)股份有限公司2025年A股股票期权激励计划(草案)
Zheng Quan Zhi Xing·2025-08-22 14:17

Core Points - The company has proposed a stock option incentive plan for 2025, aiming to enhance corporate governance and retain talent [9][10][12] - The total number of stock options to be granted is capped at 5,726,100, representing approximately 0.2144% of the company's total shares [14][15] - The plan includes an initial grant of 4,580,900 options (80% of the total) and a reserved grant of 1,145,200 options (20% of the total) [15][24] Summary by Sections Purpose of the Plan - The plan aims to align the interests of shareholders, the company, and its core team, ensuring long-term development and motivation for key personnel [9][10] Management Structure - The shareholders' meeting is the highest authority for approving the plan, while the board of directors is responsible for its execution [10][11] Incentive Recipients - The plan targets executive directors, employee directors, senior management, and other key employees, with a maximum of 201 initial recipients [12][13] Source and Quantity of Shares - The shares for the stock options will come from shares repurchased from the secondary market, with specific limits on the total number of shares that can be granted [14][15] Grant and Exercise Conditions - The exercise price for the initial grant is set at 27.93 yuan per share, based on the average trading price prior to the announcement [19][20] - The plan stipulates performance-based conditions for exercising options, including group-level financial metrics [21][24] Lock-up Regulations - There are restrictions on the transfer of shares by directors and senior management during their tenure and for a period after leaving the company [19][24]